Determining Patterns In Trial Experiences of Parkinson's Disease Patients
Study Details
Study Description
Brief Summary
Historically, participation in clinical studies is highly skewed towards particular demographic groups of people.
This study will invite several participants to gather a wide range of information on clinical trial experiences for Parkinson's Disease patients. The aim of the study is to identify the factors that limit the ability of a person to enroll in, as well as complete a clinical trial for treatment of Parkinson's Disease.
The data collected from this study will help improve future outcomes for all Parkinson's Disease patients as well as those in under-represented demographic groups.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Study Design
Outcome Measures
Primary Outcome Measures
- Number of patients who decide to enroll in an Parkinson's Disease clinical trial [3 months]
- Rate of patients who remain in Parkinson's Disease clinical trial to trial completion [12 months]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patient plans to participate in an interventional clinical trial for the condition of Parkinson's Disease
-
Patient has been diagnosed with a type of Parkinson's Disease
-
Patient is at least 50 to 80 years of age
-
Patient has access to a home internet connection in order to provide regular updates through the course of the study
Exclusion Criteria:
-
Patient has an ECOG score of 4 or higher
-
Patient is not able to provide consistent digital updates as per study requirements
-
Patient does not complete or agree to terms outlined in the Informed Consent Form
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Power Life Sciences Inc.
Investigators
- Study Director: Michael B Gill, Power Life Sciences Inc.
Study Documents (Full-Text)
More Information
Publications
- Armstrong MJ, Okun MS. Diagnosis and Treatment of Parkinson Disease: A Review. JAMA. 2020 Feb 11;323(6):548-560. doi: 10.1001/jama.2019.22360.
- McFarthing K, Rafaloff G, Baptista M, Mursaleen L, Fuest R, Wyse RK, Stott SRW. Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2022 Update. J Parkinsons Dis. 2022;12(4):1073-1082. doi: 10.3233/JPD-229002.
- Reich SG, Savitt JM. Parkinson's Disease. Med Clin North Am. 2019 Mar;103(2):337-350. doi: 10.1016/j.mcna.2018.10.014. Epub 2018 Dec 3.
- 87526739